New Blood Test Is More Accurate in Predicting Prostate Cancer Risk Than PSA


“A team of researchers from Cleveland Clinic, Louis Stokes Cleveland VA Medical Center, Kaiser Permanente Northwest, and other clinical sites have demonstrated that a new blood test known as IsoPSA detects prostate cancer more precisely than current tests in two crucial measures — distinguishing cancer from benign conditions, and identifying patients with high-risk disease.

“By identifying molecular changes in the prostate specific antigen (PSA) protein, the findings, published online last month by European Urology, suggest that once validated, use of IsoPSA may substantially reduce the need for biopsy, and may thus lower the likelihood of overdetection and overtreatment of nonlethal prostate cancer.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.

Large International Study Identifies 23 New Genetic Sites Linked to Prostate Cancer

An ongoing collaboration of more than 50 research groups around the world has identified 23 new genes or genomic regions that may contribute to the development of prostate cancer. These findings allow for a more accurate assessment of a person’s risk of developing prostate cancer. The results were published in the April, 2013, issue of Nature Genetics (doi:10.1038/ng.2560).

Including the 23 new prostate cancer susceptibility genetic loci, there are now a total of 77 known loci linked to prostate cancer. This accounts for about 30% of all familial risk for prostate cancer—the other factors for familial risk for prostate cancer are not yet defined. Continue reading…

Finasteride Reduces Risk of Prostate Cancer Diagnosis, Long-Term Study Finds

Use of finasteride reduces the risk of a prostate cancer diagnosis, but does not significantly affect mortality rates after following men for 18 years, according to the survival analysis using data from the Social Security Death Index to assess any evidence of an increased risk of death in men randomized to finasteride, a potential indicator of a “true” increased risk of high-grade disease.

Obesity Biomarkers and Prostate Cancer Study Suggests Obesity Can Accelerate Prostate Cancer Progression

A study of 500 men finds that higher body mass index, leptin blood levels, and waist-hip ratio were significantly associated with higher grade prostate cancer and suggests detection bias during prostate biopsy has resulted in
inconsistent results when the association between obesity and prostate cancer was previously studied.

A Plea for Surgical Lymph Node Staging in Advanced Prostate Cancer from European Oncologists

Clinicians advocate for a prostate cancer treatment via pelvic lymph node irradiation strategy for high-risk prostate cancer patients to be based on surgical staging. New techniques of gamma-camera-navigated surgery and fluorescence guidance to the sentinel node could improve the staging.

Targeting Constitutively Activated β1 Integrin Could Be a New Target for Prevention of Metastasis of Prostate Cancer

Researchers from the MD Anderson Cancer Center in Houston show that β1 integrin activation occurs in metastatic progression of prostate cancer and is constitutively active in late state prostate cancer cells. The study shows the integrin palys a reole in survival of metastatic prostate cancer cells in circulation. Inhibition of β1 integrin activity by antibody or knockdown results in increased apoptosis.

Prostate cancer risk reduction in men taking dutasteride, but some concerns remain

Nearly 2,800 men participated in the four-year REDUCE (REduction by DUtasteride of prostate Cancer Events) observational clinical study evaluated prostate cancer risk reduction in men taking dutasteride, a 5-alpha-reductase inhibitor (5ARI) typically used to treat enlarged prostate. Results showed that few new prostate cancers were detected during the two-year follow-up in either treatment group and no deaths were reported. However, the former dutasteride group produced double the number of cancers than the former placebo group (14 vs. 7).

Consistent epigenetic ‘signatures’ found in prostate cancer patients’ metastatic tumors

Researchers at Johns Hopkins analyzed 13 metastatic prostate tumors, finding a a consistent epigenetic signature among the samples. The discovery of the stable, epigenetic “marks” that sit on the nuclear DNA of cancer cells and alter gene expression, defies a prevailing belief that the marks vary so much within each individual’s widespread cancers that they have little or no value as targets for therapy or as biomarkers for treatment response and predicting disease severity.

Baldness by age 40 linked to prostate cancer, retrospective Australian study shows

University of Melbourne reserachers analyzed 9.448 men from the Melbourne Collaborative Cohort Study (MCCS), a prospective cohort study that was set up to investigate the role of diet and life style factors in chronic diseases including prostate, breast and bowel cancers, for hair patterns. After a more than 11 year follow-up, researchers found vertex androgenetic alopecia at age 40 years was associated with earlier age at onset of prostate cancer, and increased cumulative probability of prostate cancer up to age 76 years.